National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine
A peptide vaccine comprised of synthetic HLA-A1, -A2 and -B35 restricted survivin epitopes combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. Upon administration, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine may stimulate a cytotoxic T cell response against tumor cells that overexpress survivin, resulting in tumor cell lysis. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:survivin peptide vaccine
Abbreviation:SRV PEP VAC



Previous:HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine, HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted VEGFR1 peptide vaccine, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine
Next:HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine, Hodgkin's antigens-GM-CSF-expressing cell vaccine, HPPH, HPV 16 E7:86-93 peptide vaccine, HPV DNA plasmids therapeutic vaccine VGX-3100

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov